Harpoon Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Harpoon Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-2.0%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-2.0%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Jan 30

Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Oct 01

Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Aug 14

Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

May 28

Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Jul 30

Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio

Jul 07

Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

Mar 08

We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Nov 30

Harpoon Therapeutics: A First Look

Sep 16

Harpoon shares slide after early-stage prostate cancer study data fails to impress

Jun 04

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: HARP şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: HARP şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Harpoon Therapeutics Piyasaya Karşı Temettü Getirisi

HARP temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (HARP)	n/a
Pazarın Alt %25'i (US)	1.3%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (HARP) (3 yıla kadar)	0%

Önemli Temettü: HARP şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, HARP şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: HARP şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: HARP herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Harpoon Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Harpoon Therapeutics Files Form 15

Harpoon Therapeutics, Inc.(NasdaqCM:HARP) dropped from NASDAQ Composite Index

Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Consensus estimates of losses per share improve by 16%

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Price target increased by 16% to US$16.33

Harpoon Therapeutics, Inc. Announces Board Changes

Harpoon Therapeutics, Inc. Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Consensus EPS estimates upgraded to US$4.44 loss

Harpoon Therapeutics, Inc. announced that it expects to receive $100.162904 million in funding from a group of investors

New major risk - Share price stability

Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Harpoon Therapeutics Receives Non-Compliance Notice from Nasdaq

Harpoon Therapeutics, Inc. Announces Presentation of Interim Data for 2.15 to 12 mg Target Dose Cohorts from its Phase 1 Clinical Trial Evaluating Single-Agent HPN217 in Relapsed/Refractory Multiple Myeloma

Consensus EPS estimates fall by 52%

Price target decreased by 14% to US$45.83

Consensus estimates of losses per share improve by 10%

Forecast to breakeven in 2024

Consensus revenue estimates increase by 57%

Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Price target increased by 11% to US$5.33

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Harpoon Therapeutics, Inc. Appoints Haibo Wang as Senior Vice President of Business Development

Insufficient new directors

Price target decreased by 9.8% to US$4.81

Harpoon Therapeutics, Inc. Announces Completion of Planned Patient Enrollment in Phase 1 Study of Hpn217 in Relapsed/Refractory Multiple Myeloma

Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

Consensus EPS estimates upgraded to US$1.12 loss

Forecast to breakeven in 2024

Consensus EPS estimates fall by 20%, revenue upgraded

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 20% to US$5.43

Consensus revenue estimates fall by 45%

Insufficient new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Harpoon Therapeutics, Inc. Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma

Harpoon Therapeutics Receives a Letter from Nasdaq Regarding Minimum Closing Bid Price

Consensus revenue estimates increase by 28%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Harpoon Therapeutics, Inc. Appoints Luke Walker, M.D., as Chief Medical Officer

Harpoon Therapeutics appoints Luke Walker as CMO

Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors

Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player

Price target decreased to US$8.78

Price target decreased to US$10.67

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Harpoon Therapeutics, Inc. Announces Resignation of Georgia L. Erbez as Chief Financial Officer, Effective August 31, 2022

Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio

Harpoon Therapeutics, Inc. Announces Executive Appointments

Harpoon Therapeutics, Inc.(NasdaqGS:HARP) dropped from Russell 2000 Growth Index

Harpoon Therapeutics, Inc. Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Harpoon Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Price target decreased to US$14.50

Harpoon Therapeutics, Inc. Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome

Natalie Sacks to Leave Harpoon Therapeutics, Inc. as Chief Medical Officer, Effective June 1, 2022

Consensus forecasts updated

Price target decreased to US$23.00

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217

Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217

Harpoon Therapeutics Provides Pipeline Update for TriTAC Clinical Programs and T Cell Engager Platforms

Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition

We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.53 loss in 3Q 2020)

Price target decreased to US$26.10

Price target decreased to US$26.70